Annexon Inc. (ANNX): Price and Financial Metrics
GET POWR RATINGS... FREE!
ANNX Stock Price Chart Interactive Chart >
ANNX Price/Volume Stats
| Current price | $3.27 | 52-week high | $24.85 |
| Prev. close | $3.04 | 52-week low | $2.06 |
| Day low | $2.96 | Volume | 345,800 |
| Day high | $3.29 | Avg. volume | 554,276 |
| 50-day MA | $2.90 | Dividend yield | N/A |
| 200-day MA | $10.86 | Market Cap | 126.10M |
Annexon Inc. (ANNX) Company Bio
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in South San Francisco, CA.
Latest ANNX News From Around the Web
Below are the latest news stories about Annexon Inc that investors may wish to consider to help them evaluate ANNX as an investment opportunity.
Annexon Biosciences Appoints Bettina M. Cockroft, M.D. to its Board of DirectorsBRISBANE, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, today announced the appointment of biotech executive Bettina M. Cockroft, M.D., senior vice president and chief medical officer of Sangamo Therapeutics, Inc., to the company’s board of directors. “We are very pl |
Marin Software, QuinStreet lead postmarket gainers; Annexon, Dogness among losersGainers: Marin Software MRIN +43%, QuinStreet (QNST) +5%, Axsome Therapeutics (AXSM) +4%, CarParts.com PRTS +3%, Curis CRIS +3%.Losers: Annexon (ANNX) -5%, Dogness (DOGZ) -4%, |
Needham Maintains a Buy Rating on Annexon Biosciences (ANNX)Needham analyst Joseph Stringer maintained a Buy rating on Annexon Biosciences (ANNX – Research Report) today and set a price target of $37.00. The company's shares closed last Tuesday at $11.01. According to TipRanks.com, Stringer has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -13.0% and a 27.9% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Lexicon Pharmaceuticals, and Apellis Pharmaceuticals. Annexon Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $37.00, which is a 213.3% upside from current levels. In a report released today, H.C. |
H.C. Wainwright Maintains Their Buy Rating on Annexon Biosciences (ANNX)In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Annexon Biosciences (ANNX – Research Report), with a price target of $40.00. The company's shares closed last Tuesday at $11.01. According to TipRanks.com, Fein is a 4-star analyst with an average return of 8.0% and a 45.2% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Deciphera Pharmaceuticals, and Global Blood Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Annexon Biosciences with a $37.00 average price target, a 213.3% upside from current levels. |
Mid-Afternoon Market Update: Nasdaq Down 300 Points; Annexon Shares PlungeToward the end of trading Wednesday, the Dow traded up 0.24% to 36,711.36 while the NASDAQ fell 1.93% to 15,321.38. The S&P also fell, dropping 0.80% to 4,755.18. The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 58,040,720 cases with around 851,430 deaths. India confirmed a total of at least 35,018,350 cases and 482,550 deaths, while Brazil reported over 22,323,830 COVID-19 cases with 619,420 deaths. In total, there were at least 295,735,790 cases of COVID-19 worldwide with more than 5,476,550 deaths. Leading and Lagging Sectors Materials shares climbed 1.5% on Wednesday. Meanwhile, top gainers in the sector included GoldMining Inc. (NYSE: GLDG ), up 15% and Cleveland-Cliffs Inc. (NYSE: CLF ) up 7%. In trading on Wednesday, real estate s... |
ANNX Price Returns
| 1-mo | 28.24% |
| 3-mo | -36.38% |
| 6-mo | -76.89% |
| 1-year | -84.52% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -71.54% |
| 2021 | -54.10% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...